Matthews & Associates Law Firm is reviewing Laparoscopic Morcellator Lawsuits nationwide for women who were diagnosed with uterine cancer, including leimyosarcoma (LMS) or other types of cancer following a hysterectomy or fibroid removal which employed a power morcellator.
An estimated one of every 350 women undergoing a hysterectomy for removal of the uterus or uterine fibroids may have an undiagnosed sarcoma, which doctors cannot detect prior to the surgery. Additionally, they estimate that one in 500 women has an aggressive form of cancer called leiomyosarcoma (LMS). Laparoscopic power morcellators used in such cases can lead to serious problems.
Morcellator can spread Cancer
Some 600,000 women undergo hysterectomy each year in the U.S. Morcellators are used in some 55,000-75,000 procedures yearly. Morcellator blades cut tissues into smaller pieces to make them easier to remove. But morcellators often leave behind tiny pieces of tissue. If those pieces contain cancerous cells that are sliced and diced with a morcellator, aggressive cancer tissue can be spread throughout the abdomen and other parts of the body, significantly increasing the risk of cancer and even death. Many women have been diagnosed with advanced stage uterine cancer following a laparoscopic hysterectomy or robotic hysterectomy, where leiomyosarcoma, endometrial stromal sarcoma or other cancer has metastasized to the pelvis, bladder, lungs or other remote areas.
Consider this analogy of a morcellator cancer link. One can think of cancer as an intact egg yolk, contained. Once that yolk is broken, it can spread throughout the body.
FDA Warning: Hysterectomy Cancer Risk
In April 2014, FDA published a Safety Warning recommending morcellators not be used in the treatment of uterine fibroids or hysterectomies. The agency wrote that laparoscopic power morcellation performed in women with undiagnosed uterine sarcoma can spread the cancerous tissue within the abdomen and pelvis, significantly worsening the woman’s likelihood of long-term survival. The agency also noted no reliable method exists for predicting whether a woman with fibroids may have a uterine sarcoma. Therefore, the agency “discourages the use of laparoscopic power morcellation during hysterectomy or myomectomy for uterine fibroids.”
Then on Nov. 24, 2014, FDA upped the ante on its morcellator stance, warning against the use of laparoscopic power morcellators for most women undergoing hysterectomy or myomectomy for uterine fibroids. The agency said that, “Health care providers and patients should carefully consider available alternative treatment options for the removal of symptomatic uterine fibroids.”
Doctors push back
Some gynecologists, meanwhile, have begun to push back, arguing that the agency is denying women the right to morcellator use which is less invasive than previously used technology for hysterectomy and fibroid removal.
Laparoscopic Morcellator Lawsuit Attorney
If you or someone you know has had a hysterectomy and was subsequently diagnosed with uterine cancer, please contact our offices for a free legal consultation. You may have a valid claim against the manufacturer of the power morcellator used during hysterectomy surgery.
Matthews & Associates has helped thousands of people injured by dangerous medical devices, including transvaginal or pelvic mesh. Please view our testimonials to see how we have helped others in medical device or dangerous drug litigation.